National Comprehensive Cancer Network® (NCCN®) is pleased to announce a collaboration with Pfizer Global Medical Grants (Pfizer) and Astellas Pharma, Inc. (Pharma) to offer a new grant opportunity. This research grant will promote the advancement of scientific knowledge concerning the mechanisms of actions, underlying biology, and clinical effectiveness of enzalutamide in prostate cancer.
The overall aim of this RFP is to develop innovative studies to support the design and performance of clinical, pre-clinical and correlative studies of enzalutamide in the treatment of prostate cancer. Clinical trials, prospective studies, and retrospective correlative studies of enzalutamide treatment trials or datasets are encouraged. It is hoped proposals submitted in response to this RFP will be useful in guiding further development of enzalutamide in combination with other therapies. Studies with correlative endpoints will be accepted, and studies that retrospectively analyze biomarkers (tissue, liquid biopsy, and other assays) within prospective trials or datasets will be accepted.
NCCN views this collaboration with Pfizer and Astellas as clear recognition of the advantages offered to NCCN Member Institutions through the NCCN Oncology Research Program. We hope you and your colleagues will be interested in this opportunity.
To be considered for funding, LOIs must be submitted by 5:00 pm ET, May 14, 2021. Please direct questions regarding this RFP to Nicole Kamienski at email@example.com with the subject line, “Enzalutamide 2021 Project.”